EMPOWER-Lung 1: A Randomized, Open-Label, Multi-National, Phase III Trial of Cemiplimab, A Human PD-1 Monoclonal Antibody, Versus Chemotherapy In First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With PD-L1 >= 50%

Sriuranpong, V.Altundag, O.Clingan, P.Rizvi, N.Frontera, O. ArenSezer, A.Paydas, S.Shavdia, M.Bondarenko, I.Gladkov, O.2023-04-182023-04-1820180923-7534http://hdl.handle.net/11727/8819enginfo:eu-repo/semantics/closedAccessEMPOWER-Lung 1: A Randomized, Open-Label, Multi-National, Phase III Trial of Cemiplimab, A Human PD-1 Monoclonal Antibody, Versus Chemotherapy In First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With PD-L1 >= 50%Conference Object29Supplement 10000459294800115